Association between Clinical Activity Score and Serum Interleukin-6, Interleukin-8 and Interleukin-10 during Systemic Glucocorticoid Treatment for Active Moderate-to-Severe Graves’ Orbitopathy

2021 ◽  
pp. 1-6
Author(s):  
Mariya Asenova Stoynova ◽  
Alexander Dimitrov Shinkov ◽  
Georgi Kirilov Georgiev ◽  
Roussanka Dimitrova Kovatcheva
Keyword(s):  
Interleukin 6 ◽  
Interleukin 10 ◽  
Interleukin 8 ◽  
Activity Score ◽  
Clinical Activity ◽  
Glucocorticoid Treatment ◽  
Clinical Activity Score ◽  
Systemic Glucocorticoid ◽  
Graves Orbitopathy

Graves’ Orbitopathy: Extraocular Muscle/Total Orbit Area Ratio is Positively Related to the Clinical Activity Score

2011 ◽  
Vol 22 (3) ◽  
pp. 301-308 ◽  
Author(s):  
Rosario Le Moli ◽  
Alessandro Pluchino ◽  
Vincenzo Muscia ◽  
Concetto Regalbuto ◽  
Bruno Luciani ◽  
...  
Keyword(s):  
Extraocular Muscle ◽  
Area Ratio ◽  
Activity Score ◽  
Clinical Activity ◽  
Clinical Activity Score ◽  
Graves Orbitopathy

scholarly journals Comparison of the Effectiveness and Tolerability of Intravenous or Oral Glucocorticoids Associated with Orbital Radiotherapy in the Management of Severe Graves’ Ophthalmopathy: Results of a Prospective, Single-Blind, Randomized Study

2001 ◽  
Vol 86 (8) ◽  
pp. 3562-3567 ◽  
Author(s):  
Claudio Marcocci ◽  
Luigi Bartalena ◽  
Maria Laura Tanda ◽  
Luca Manetti ◽  
Enrica Dell’Unto ◽  
...  
Keyword(s):  
Side Effects ◽  
Activity Score ◽  
Clinical Activity ◽  
High Dose ◽  
Glucocorticoid Treatment ◽  
Orbital Radiotherapy ◽  
Oral Glucocorticoid ◽  
Clinical Activity Score ◽  
Graves Ophthalmopathy ◽  
Significant Difference

Eighty-two consecutive patients with moderate-to-severe and active Graves’ ophthalmopathy were randomly treated with orbital radiotherapy combined with either oral (prednisone; starting dose, 100 mg/d; withdrawal after 5 months) or iv (methylprednisolone; 15 mg/kg for four cycles and then 7.5 mg/kg for four cycles; each cycle consisted of two infusions on alternate days at 2-wk intervals) glucocorticoids. The two groups did not differ for age, gender, duration of hyperthyroidism and ophthalmopathy, prevalence of smokers, thyroid volume, and pretreatment ocular conditions. Both groups of patients received radioiodine therapy shortly before treatment for Graves’ ophthalmopathy. Follow-up lasted for 12 months. A significant reduction in proptosis (from 23.2 ± 3.0 to 21.6 ± 1.2 mm in the iv glucocorticoid group, P < 0.0001; and from 23 ± 1.8 to 21.7± 1.8 mm in oral glucocorticoid group, P < 0.0001) and in lid width (from 13.3 ± 2.5 to 11.8 ± 2.2 mm, and from 13.6 ± 2.0 to 11.5 ± 1.9 mm, respectively; P < 0.001 in both cases) occurred, with no difference between the two groups. Diplopia significantly improved in both groups: it disappeared in 13 of 27 (48.1%) iv glucocorticoid patients (P < 0.005) and in 12 of 33 (36.4%) oral glucocorticoid patients (P < 0.03). The degree of amelioration of diplopia did not significantly differ between the two groups (P = 0.82). Optic neuropathy improved in 11 of 14 iv glucocorticoid (P < 0.01) and only in 3 of 9 oral glucocorticoid (P = 0.57) patients, with no significant difference in these outcomes. The Clinical Activity Score decreased from 4.5 ± 1.2 to 1.7 ± 1.0 (P < 0.0001) in the iv glucocorticoid group and from 4.2 ± 1.1 to 2.2 ± 1.2 (P < 0.0001) in the oral glucocorticoid group; final Clinical Activity Score was significantly lower in iv glucocorticoid than in oral glucocorticoid patients (P < 0.01). By self-assessment evaluation, 35 (85.3%) iv glucocorticoid and 30 (73.2%) oral glucocorticoid patients reported an improvement of ocular conditions (P = 0.27). Overall, both treatments produced favorable effects in most patients, but responders in the iv glucocorticoid group (36 of 41, 87.8%) were more than in the oral glucocorticoid group (26 of 41, 63.4%) (P < 0.02). Moreover, iv glucocorticoid treatment was better tolerated than oral glucocorticoid treatment. Side effects occurred in 23 (56.1%) iv glucocorticoid and 35 (85.4%) oral glucocorticoid patients (P < 0.01); in particular, cushingoid features developed in 5 of the former and 35 of the latter patients. One iv glucocorticoid patient had severe hepatitis of undetermined origin at the end of glucocorticoid treatment, followed by spontaneous recovery. In conclusion, high-dose iv glucocorticoid and oral glucocorticoid (associated with orbital radiotherapy) are effective in the management of severe Graves’ ophthalmopathy, but the iv route seems to be more effective and better tolerated than the oral route and associated with a lower rate of side effects.

scholarly journals Choroidal vascularity index in thyroid-associated ophthalmopathy: a cross-sectional study

2021 ◽  
Vol 8 (1) ◽  
Author(s):  
Pasquale Loiudice ◽  
Marco Pellegrini ◽  
Michele Marinò ◽  
Barbara Mazzi ◽  
Ilaria Ionni ◽  
...  
Keyword(s):  
Cross Sectional Study ◽  
Activity Score ◽  
Enhanced Depth Imaging ◽  
Clinical Activity ◽  
Healthy Controls ◽  
Cross Sectional ◽  
Clinical Activity Score ◽  
Significant Difference ◽  
Thyroid Associated Ophthalmopathy ◽  
Imagej Software

Abstract Background Hemodynamic changes have been observed in patients with Graves’ disease. The aim of our study was to evaluate choroidal vascular change using the choroidal vascularity index (CVI) in patients with thyroid-associated ophthalmopathy (TAO). Methods In this cross-sectional observational study, 40 patients affected by TAO were recruited. Forty healthy individuals, matched for age and sex, served as controls. Foveal enhanced-depth imaging optical coherence tomography scans were obtained from all participants. Images were binarized using the ImageJ software and luminal area (LA) and total choroidal area (TCA) were measured. CVI was calculated as the proportion of LA to TCA. The relation between CVI or subfoveal choroidal thickness (SFCT) and clinical activity score, exophthalmometric value, diplopia status, gender, and age was evaluated. Results CVI was significantly higher in patients with TAO (P = 0.004). No significant difference was observed in SFCT (P = 0.200) and TCA (P = 0.153) comparing TAO patients and healthy controls. LA was significantly higher in TAO group (P = 0.045). On multiple regression analysis, CVI was associated with TCA (P = 0.043). No association was found between SFCT or CVI and TCA, clinical activity score, exophthalmometric value, Inami value, diplopia status, gender or age (P > 0.05). Conclusions This is the first study that has demonstrated an increase in CVI in eyes with TAO compared with healthy controls and has assessed its association with clinical features.

A Pilot Study Evaluating 99mTc-anti-TNF-alpha Scintigraphy in Graves' Ophtalmopathy Patients with Different Clinical Activity Score

2013 ◽  
Vol 45 (10) ◽  
pp. 765-768 ◽  
Author(s):  
E. Rebelo Pinto ◽  
F. Lopes ◽  
S. de Souza ◽  
L. da Fonseca ◽  
M. Vaisman ◽  
...  
Keyword(s):  
Pilot Study ◽  
Activity Score ◽  
Tnf Alpha ◽  
Clinical Activity ◽  
Clinical Activity Score

scholarly journals Translation and validation of the Indian Takayasu clinical activity score (ITAS2010) for the Brazilian Portuguese language

2019 ◽  
Vol 59 (1) ◽  
Author(s):  
Scheila Fritsch ◽  
Rafaela Martinez Copes ◽  
Bruna Savioli ◽  
Mariana Freitas de Aguiar ◽  
Rozana Mesquita Ciconelli ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Disease Activity ◽  
Correlation Coefficient ◽  
Intraclass Correlation ◽  
Brazilian Portuguese ◽  
Activity Score ◽  
Inactive Disease ◽  
Clinical Activity ◽  
Additional Tool ◽  
Clinical Activity Score

Abstract Background The Indian Takayasu Clinical Activity Score (ITAS2010) was developed in 2010 as an assessment tool for disease activity in patients with Takayasu arteritis (TA). It has since been widely used in different studies and in clinical practice for the management of patients with TA. The present study aims to translate the ITAS2010 into Brazilian Portuguese language and to validate it for use in clinical practice in Brazil. Methods For this cross-sectional study, the ITAS2010 was translated in accordance with the guidelines described by Beaton et al. and then applied with 27 patients with TA on three assessments by two rheumatologists working independently. To measure interrater agreement, the assessments were performed on the same day within approximately 1 hour. One of the rheumatologists performed a second evaluation of patients with TA within 7 to 14 days to measure intrarater agreement. Results The correlation coefficient for the ITAS2010 score between the two raters was high (r = 0.916; p < 0.0001), as well as the intraclass correlation coefficient (ICC) [0.918 with a 95% confidence interval (95CI): 0.828–0.962]. The correlation coefficient and the ICC for intrarater agreement were moderate for ITAS2010 (r = 0.633; p < 0.0001 and ICC = 0.594; 95CI: 0.292–0.790). The ITAS2010 at baseline was compared with the physician’s global assessment (PGA) and with Kerr’s criteria for detecting disease activity in TA. Higher ITAS2010 scores were observed in patients with active and grumbling/persistent disease than in those presenting inactive disease according to the PGA [1.5 (0.0–3.0) vs. 0.0 (0.0–0.0); p = 0.0025]. Patients with active disease according to the Kerr’s criteria had also higher ITAS2010 scores than those considered in remission [3.0 (3.0–7.0) vs. 0.0 (0.0–0.0); p = 0.0068]. Conclusions The Brazilian Portuguese version of the ITAS2010 is a valid and reproducible tool for the assessment of disease activity in TA and it is an additional tool for the routine evaluation of Brazilian patients with TA.

Sign in / Sign up

Export Citation Format

Share Document